Clinical Trial: A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus.

U.S., May 27 -- ClinicalTrials.gov registry received information related to the study (NCT07606521) titled 'A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus.' on May 11.

Brief Summary: This is a randomized, parallel group, double-blind, active-controlled, clinical pharmacology study to compare Pharmacokinetics, Pharmacodynamics and safety of PB018 versus Ocrevus in patients with Multiple Sclerosis.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Multiple Sclerosis

Intervention: BIOLOGICAL: US-Ocrevus

Intravenous(IV) infusion

BIOLOGICAL: PB018

Intravenous(IV) infusion

BIOLOGICAL: EU-Ocrevus

Intravenous(IV) infusion

Recruitment Status: NOT_YET_RECRUI...